
    
      This is a phase 1/2, open-label, first-in-human, multi-center study to characterize the
      safety and tolerability of RPTR-168 administered i.v. as a monotherapy in patients with
      relapsed/refractory metastatic or locally-advanced HPV-16 E6/E7 positive tumors (HNSCC,
      cervical) and melanoma.

      The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion
      (Phase 2).
    
  